Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC – Research ...

New! Sign up for our free email newsletter.